1)長尾毅彦:Xa因子阻害薬―最新のエビデンス.臨床神経学51:1007-1010, 2011
2)Harenberg J, et al:Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays;Reduction of interassay variability. J Thromb Thrombolysis 32:267-271, 2011
3)Patel MR, et al:Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891, 2011
4)Albers GW, et al:Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation;A randomized trial. JAMA 293:690-698, 2005
5)Hori M:The safety and efficacy of rivaroxaban for prevention of stroke in Japanese patients with non-valvular atrial fibrillation. ⅩⅩⅢ Congress of the International Society of Thrombosis and Haemostasis 2011, Kyoto, 2011
6)梶川麻里子,上田仁司:リバーロキサバンの臨床開発.BIO Clinica 27:50-54, 2012
7)Connolly SJ, et al:Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151, 2009
8)Connolly SJ, et al:Apixaban in patients with atrial fibrillation. N Engl J Med 364:806-817, 2011
9)Ruff CT, et al:Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation;Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48(ENGAGE AF-TIMI 48). Am Heart J 160:635-641, 2010